Bioventus Inc.
BVS
$9.51
$0.141.49%
| Weiss Ratings | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.81 | |||
| Price History | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.16% | |||
| 30-Day Total Return | -7.85% | |||
| 60-Day Total Return | -8.91% | |||
| 90-Day Total Return | -17.95% | |||
| Year to Date Total Return | -10.54% | |||
| 1-Year Total Return | 88.69% | |||
| 2-Year Total Return | 741.59% | |||
| 3-Year Total Return | -28.44% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -34.84% | |||
| 52-Week Low % Change | 140.26% | |||
| Price | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.38 | |||
| 52-Week Low Price | $3.90 | |||
| 52-Week Low Price (Date) | Apr 30, 2024 | |||
| 52-Week High Price (Date) | Nov 04, 2024 | |||
| Valuation | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 619.89M | |||
| Enterprise Value | 972.03M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.52 | |||
| Earnings Per Share Growth | -79.18% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.07 | |||
| Price/Book (Q) | 4.16 | |||
| Enterprise Value/Revenue (TTM) | 1.70 | |||
| Price | $9.51 | |||
| Enterprise Value/EBITDA (TTM) | 12.06 | |||
| Enterprise Value/EBIT | 25.13 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 65.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 919 474 6700 | |||
| Address | 4721 Emperor Boulevard Durham, NC 27703 | |||
| Website | www.bioventus.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 6.74% | |||
| Profit Margin | -5.85% | |||
| Management Effectiveness | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.14% | |||
| Return on Equity | -- | |||
| Income Statement | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 573.28M | |||
| Total Revenue (TTM) | 573.28M | |||
| Revenue Per Share | $8.76 | |||
| Gross Profit (TTM) | 388.23M | |||
| EBITDA (TTM) | 80.61M | |||
| EBIT (TTM) | 38.68M | |||
| Net Income (TTM) | -33.54M | |||
| Net Income Avl. to Common (TTM) | -33.54M | |||
| Total Revenue Growth (Q YOY) | 13.45% | |||
| Earnings Growth (Q YOY) | 95.85% | |||
| EPS Diluted (TTM) | -0.52 | |||
| EPS Diluted Growth (Q YOY) | 97.52% | |||
| Balance Sheet | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 41.58M | |||
| Cash Per Share (Q) | $0.64 | |||
| Total Current Assets (Q) | 275.61M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 185.60M | |||
| Current Ratio (Q) | 1.310 | |||
| Book Value Per Share (Q) | $2.25 | |||
| Total Assets (Q) | 727.96M | |||
| Total Current Liabilities (Q) | 210.40M | |||
| Total Debt (Q) | 356.06M | |||
| Total Liabilities (Q) | 542.35M | |||
| Total Common Equity (Q) | 147.94M | |||
| Cash Flow | BVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 22.96M | |||
| Cash from Financing (TTM) | -54.58M | |||
| Net Change in Cash (TTM) | 4.62M | |||
| Levered Free Cash Flow (TTM) | 59.83M | |||
| Cash from Operations (TTM) | 38.80M | |||
